Comparative immunohistochemical analysis of aurora-A and aurora-B expression in human glioblastomas. Associations with proliferative activity and clinicopathological features

Pathology Research and Practice

Volumn 205, Issue 11, 2009, Pages 765-773

  Samaras, Vassilis ^a   Stamatelli, Angeliki ^a   Samaras, Efstathios ^b   Arnaoutoglou, Christos ^c   Arnaoutoglou, Marianthi ^d   Stergiou, Ioanna ^e   Konstantopoulou, Paraskevi ^e   Varsos, Vassilis ^b   Karameris, Andreas ^f   Barbatis, Calypso ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b RED CROSS HOSPITAL   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e General Hospital of Lamia   (Greece)

^f 417 VA Hospital (NIMTS)   (Greece)

Author keywords

Aurora A; Aurora B; Chemotherapy; Glioblastoma; Prognosis

Indexed keywords

AURORA A KINASE; AURORA B KINASE; CARMUSTINE; KI 67 ANTIGEN; TEMOZOLOMIDE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MULTIPLE CYCLE TREATMENT; PRIMARY TUMOR; PROGNOSIS; PROTEIN FUNCTION; SURVIVAL TIME; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BRAIN NEOPLASMS; CELL PROLIFERATION; CEREBRAL CORTEX; COMBINED MODALITY THERAPY; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROTEIN-SERINE-THREONINE KINASES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 71749103630     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2009.06.011     Document Type: Article

References (41)

1. Araki K., Nozaki K., Ueba T., Tatsuka M., and Hashimoto N. High expression of Aurora-B/Aurora and Ipll-like midbody-associated protein (AIM-1) in astrocytomas. J. Neurooncol. 67 1-2 (2004) 53-64
2. Barrié M., Couprie C., Dufour H., Figarella-Branger D., Muracciole X., Hoang-Xuan K., Braguer D., Martin P.M., Peragut J.C., Grisoli F., and Chinot O. Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. Ann. Oncol. 16 7 (2005) 1177-1184
3. Bouvier-Labit C., Chinot O., Ochi C., Gambarelli D., Dufour H., and Figarella-Branger D. Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropathol. Appl. Neurobiol. 24 5 (1998) 381-388
4. Burum-Auensen E., De Angelis P.M., Schjølberg A.R., Kravik K.L., Aure M., and Clausen O.P. Subcellular localization of the spindle proteins Aurora A, Mad2, and BUBR1 assessed by immunohistochemistry. J. Histochem. Cytochem. 55 5 (2007) 477-486
5. Carmena M., and Earnshaw W.C. The cellular geography of aurora kinases. Nat. Rev. Mol. Cell Biol. 4 11 (2003) 842-854
6. Compérat E., Camparo P., Haus R., Chartier-Kastler E., Radenen B., Richard F., Capron F., and Paradis V. Aurora-A/STK-15 is a predictive factor for recurrent behaviour in non-invasive bladder carcinoma: a study of 128 cases of non-invasive neoplasms. Virchows. Arch. 450 4 (2007) 419-424
7. Donato V., Papaleo A., Castrichino A., Banelli E., Giangaspero F., Salvati M., and Delfini R. Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide. Tumori 93 3 (2007) 248-256
8. Fujita M., Mizuno M., Nagasaka T., Wakabayashi T., Maeda K., Ishii D., Arima T., Kawajiri A., Inagaki M., and Yoshida J. Aurora-B dysfunction of multinucleated giant cells in glioma detected by site-specific phosphorylated antibodies. J. Neurosurg. 101 6 (2004) 1012-1017
9. Furukawa J., Miyake H., Takenaka A., Hara I., and Fujisawa M. Persistent expression of Aurora-A after neoadjuvant hormonal therapy as a predictor of a poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer. BJU Int. 100 2 (2007) 310-314
10. Gibson S.E., Zeng W.F., Weil R.J., and Prayson R.A. Aurora B kinase expression in ependymal neoplasms. Appl. Immunohistochem. Mol. Morphol. 16 3 (2008) 274-278
11. Giet R., Petretti C., and Prigent C. Aurora kinases, aneuploidy and cancer, a coincidence or a real link?. Trends Cell Biol. 15 5 (2005) 241-250
12. Hagedorn M., Delugin M., Abraldes I., Allain N., Belaud-Rotureau M.A., Turmo M., Prigent C., Loiseau H., Bikfalvi A., and Javerzat S. FBXW7/hCDC4 controls glioma cell proliferation in vitro and is a prognostic marker for survival in glioblastoma patients. Cell Div. 27 (2007) 2:9
13. Katayama H., Brinkley W.R., and Sen. S. The aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev. 22 4 (2003) 451-464
14. Kleihues P., Burger P.C., Aldape K.D., et al. Glioblastoma. In: Louis D.N., Ohgaki H., Wiestler O.D., and Cavenee W.K. (Eds). WHO Classification of Tumours of the Central Nervous System (2007), IARC Press, Lyon 33-49
15. Klein A., Reichardt W., Jung V., Zang K.D., Meese E., and Urbschat S. Overexpression and amplification of STK15 in human gliomas. Int. J. Oncol. 25 6 (2004) 1789-1794
16. Kleinberg L.R., Weingard J., Burger P., Carson K., Grossman S.A., Li K., Olivi A., Wharam M.D., and Brem H. Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management. Cancer Invest. 22 1 (2004) 1-9
17. Kurahashi T., Miyake H., Hara I., and Fujisawa M. Significance of Aurora-A expression in renal cell carcinoma. Urol. Oncol. 25 2 (2007) 128-133
18. Kurai M., Shiozawa T., Shih H.C., Miyamoto T., Feng Y.Z., Kashima H., Suzuki A., and Konishi I. Expression of aurora kinases A and B in normal, hyperplastic, and malignant human endometrium: Aurora B as a predictor for poor prognosis in endometrial carcinoma. Hum. Pathol. 36 12 (2005) 1281-1288
19. Lassmann S., Shen Y., Jütting U., Whiele P., Walch A., Gitsch G., Hasenburg A., and Werner M. Aurora-a is a predictive marker for stage III epithelial ovarian cancers. Verh. Dtsch. Ges. Pathol. 91 (2007) 225-232
20. Marumoto T., Zhang D., and Saya. H. Aurora-A - a guardian of poles. Nat. Rev. Cancer 5 1 (2005) 42-50
21. Meraldi P., Honda R., and Nigg E.A. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr. Opin. Genet. Dev. 14 1 (2004) 29-36
22. Moskowitz S.I., Jin T., and Prayson. R.A. Role of MIB1 in predicting survival in patients with glioblastomas. J. Neurooncol. 76 2 (2006) 193-200
23. Parsa A.T., Wachhorst S., Lamborn K.R., Prados M.D., McDermott M.W., Berger M.S., and Chang S.M. Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults. J. Neurosurg. 102 4 (2005) 622-628
24. Perry J., Chambers A., Spithoff K., and Laperriere N. Gliadel wafers in the treatment of malignant glioma: a systematic review. Curr. Oncol. 14 5 (2007) 189-194
25. Prados M.D., Yung W.K., Fine H.A., Greenberg H.S., Junck L., Chang S.M., Nicholas M.K., Robins H.I., Mehta M.P., Fink K.L., Jaeckle K.A., Kuhn J., Hess K.R., and Schold Jr. S.C. North American Brain Tumor Consortium study. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neuro Oncol. 6 1 (2004) 33-37
26. Qi G., Ogawa I., Kudo Y., Miyauchi M., Siriwardena B.S., Shimamoto F., Tatsuka M., and Takata T. Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer. Virchows Arch. 450 3 (2007) 297-302
27. Reichardt W., Jung V., Brunner C., Klein A., Wemmert S., Romeike B.F., Zang K.D., and Urbschat S. The putative serine/threonine kinase gene STK15 on chromosome 20q13.2 is amplified in human gliomas. Oncol. Rep. 10 5 (2003) 1275-1279
28. Rojanala S., Han H., Muñoz R.M., Browne W., Nagle R., Von Hoff D.D., and Bearss D.J. The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. Mol. Cancer Ther. 3 4 (2004) 451-457
29. Schröder R., Bien K., Kott R., Meyers I., and Vössing R. The relationship between Ki-67 labeling and mitotic index in gliomas and meningiomas: demonstration of the variability of the intermitotic cycle time. Acta Neuropathol. 82 5 (1991) 389-394
30. Sen S., Zhou H., Zhang R.D., Yoon D.S., Vakar-Lopez F., Ito S., Jiang F., Johnston D., Grossman H.B., Ruifrok A.C., Katz R.L., Brinkley W., and Czerniak B. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J. Natl. Cancer Inst. 94 17 (2002) 1320-1329
31. Simon J.M., Toubiana T., Lang P., Taillibert S., and Mazeron J.J. Radiotherapy for glioblastomas: from radiobiology to concomitant chemotherapy. Cancer Radiother. 9 5 (2005) 322-331
32. Sorrentino R., Libertini S., Pallante P.L., Troncone G., Palombini L., Bavetsias V., Spalletti-Cernia D., Laccetti P., Linardopoulos S., Chieffi P., Fusco A., and Portella G. Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J. Clin. Endocrinol. Metab. 90 2 (2005) 928-935
33. Stark A.M., Nabavi A., Mehdorn H.M., and Blömer U. Glioblastoma multiforme-report of 267 cases treated at a single institution. Surg. Neurol. 63 2 (2005) 162-169
34. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., and Mirimanoff R.O. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352 10 (2005) 987-996
35. Sun L., Li D., Dong X., Yu H., Dong J.T., Zhang C., Lu X., and Zhou J. Small-molecule inhibition of aurora kinases triggers spindle checkpoint-independent apoptosis in cancer cells. Biochem. Pharmacol. 75 5 (2008) 1027-1034
36. Tanaka E., Hashimoto Y., Ito T., Okumura T., Kan T., Watanabe G., Imamura M., Inazawa J., and Shimada Y. The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma. Clin. Cancer Res. 11 5 (2005) 1827-1834
37. Tong T., Zhong Y., Kong J., Dong L., Song Y., Fu M., Liu Z., Wang M., Guo L., Lu S., Wu M., and Zhan Q. Overexpression of Aurora-A contributes to malignant development of human esophageal squamous cell carcinoma. Clin. Cancer Res. 10 21 (2004) 7304-7310
38. Vischioni B., Oudejans J.J., Vos W., Rodriguez J.A., and Giaccone G. Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol. Cancer Ther. 5 11 (2006) 2905-2913
39. Wang X.X., Liu R., Jin S.Q., Fan F.Y., and Zhan Q.M. Overexpression of aurora-A kinase promotes tumor cell proliferation and inhibits apoptosis in esophageal squamous cell carcinoma cell line. Cell Res. 16 4 (2006) 356-366
40. Westphal M., Ram Z., Riddle V., Hilt D., Bortey E., and Executive Committee of the Gliadel Study Group. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir. (Wien) 148 3 (2006) 269-275
41. Zeng W.F., Navaratne K., Prayson R.A., and Weil R.J. Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme. J. Clin. Pathol. 60 2 (2007) 218-221